Priveterra Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with other businesses. The company was incorporated in 2020 and is based in Fort Lauderdale, Florida.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
NT 10-Q - Priveterra Acquisition Corp. II (0001821606) (Filer)
8-K - Priveterra Acquisition Corp. II (0001821606) (Filer)
NT 10-K - Priveterra Acquisition Corp. II (0001821606) (Filer)
8-K - AEON Biopharma, Inc. (0001837607) (Filer)
S-1/A - AEON Biopharma, Inc. (0001837607) (Filer)
10-Q - AEON Biopharma, Inc. (0001837607) (Filer)
8-K - AEON Biopharma, Inc. (0001837607) (Filer)
S-1/A - AEON Biopharma, Inc. (0001837607) (Filer)
8-K - AEON Biopharma, Inc. (0001837607) (Filer)
8-K - AEON Biopharma, Inc. (0001837607) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
3 - AEON Biopharma, Inc. (0001837607) (Issuer)
3 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
Fastest customizable press release news feed in the world
Priveterra Acquisition Corp. II (NASDAQ:PMGMU, PMGM, PMGMW))) (the "Company") today announced that on April 29, 2024, the Company received a notice (the "10-K Notice") from the staff of the Nasdaq Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rules for continued listing and, accordingly, such delinquency may serve as a separate basis for the delisting of the Company's securities from Nasdaq. The 10-K Notice also states that the Nasdaq Hearings Panel (the "P
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is anticipated to readout this fall $50 million financing provides sufficient cash runway to fund operations beyond the anticipated Phase 2 data announcement this fall IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, annou
Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/ The resulting co
Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra" and, after the consummation of its pending business combination (the "Business Combination") and following its name change to AEON Biopharma, Inc., "New AEON") today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock ("New AEON Common Stock") and New AEON warrants to be listed on NYSE American LLC ("NYSE") upon the Business Combination with AEON Biopharma, Inc., ("AEON") following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home
Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra" and, after the consummation of its pending business combination (the "Business Combination") and following its name change to AEON Biopharma, Inc., "New AEON") today announced that, upon the Business Combination with AEON Biopharma, Inc, ("AEON") following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc., New AEON Common Stock will be listed on NYSE American LLC ("NYSE"). The decision to list on NYSE was made in connection with the Business Combination and enables the combined company to be listed alongside other innovative companies that are also listed on NYSE. T
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company, today announced that a total of up to $125 million in funding has been arranged in connection with the proposed business combination between AEON and Priveterra. The funding includes approximately $50 million of committed financing from existing (including $20 million of previously announced financing) and new AEON investors as
IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company, today announced that at least $20 million in additional funding has been committed by existing AEON investors. The commitments have been delivered in connection with the proposed business combination between AEON and Priveterra announced on December 13, 2022, and represent nearly half of the minimum cash requirement for the pro
AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp., ((PMGM) (Priveterra), a special purpose acquisition company, today announced the filing of Form S-4 Registration Statement ("S-4") with the U.S. Securities and Exchange Commission ("SEC") regarding the recently announced business combination between the two companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221226005060/en/ To learn more about AEON and the development of its uniquely positioned the
– Topline data expected to be announced in 2H 2023 – – Topline data from the Company's Phase 2 trial in preventive treatment of chronic migraine expected to be announced in 1H 2024 – IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) for therapeutic indications, and Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company (SPAC), today announced the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of ep
– Positive topline data from Phase 2 study of ABP-450 for cervical dystonia announced in September 2022 – – Topline data from Phase 2 study of ABP-450 for episodic migraine expected in Q4 2023 – –Robert Palmisano of Priveterra to become chairman of the Board of Directors; combined company to be led by AEON CEO Marc Forth – – Transaction values the combined company at a post-money equity value of $475.5M and is expected to provide $276M in gross cash proceeds – – Merger anticipated to close in 1H 2023 – IRVINE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a private clinical-stage biopharmaceutical company focused on the developmen
This live feed shows all institutional transactions in real time.
SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13G/A - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13D/A - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13D - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13D - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13G/A - Priveterra Acquisition Corp. (0001837607) (Subject)
SC 13G/A - Priveterra Acquisition Corp. (0001837607) (Subject)
SC 13G - Priveterra Acquisition Corp. (0001837607) (Subject)